NeuroBo Pharmaceuticals, Inc. announced on January 14, 2022, Mr. Douglas J. Swirsky provided notice of his resignation from the Board of Directors, effective immediately. Andrew I. Koven, a current director of the Company was elected Chairman of the Board and Michael Salsbury, a current director of the Company was appointed to the Audit Committee of the Board and appointed Chairman of the Audit Committee. As a result, the Audit Committee of the Board currently consists of Jason Groves, Andrew I. Koven, Michael Salsbury.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.98 USD | +4.46% | -3.63% | +7.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.67% | 19.53M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.31% | 22.48B | |
-9.74% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- Neurobo Pharmaceuticals, Inc. Announces Management Changes